Alshinnawy Ameera Saeed, Badiea Elham A, Swelam Mahmoud Saad, Sayed Ahmed A, Mohamed Mohamed R
Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt.
Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mol Neurobiol. 2025 Jul 18. doi: 10.1007/s12035-025-05194-9.
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), characterized by neuroinflammation and neurodegeneration. Emerging evidence links gut microbiota dysbiosis to immune dysregulation and MS progression. While extensive research has been conducted in Western populations, region-specific studies are needed to assess the influence of local genetic and environmental factors. This study investigates gut microbiota alterations in Egyptian MS patients using Oxford Nanopore sequencing to identify microbial signatures associated with disease progression. Fecal samples from 33 newly diagnosed MS patients (20 with relapsing-remitting MS [RRM] and 13 with Progressive MS [PMS]) and 10 healthy controls were analyzed using long-read Oxford Nanopore sequencing of the full 16S rRNA gene. MS patients exhibited increased microbial richness but reduced evenness, with distinct gut microbiome profiles. Progressive MS was characterized by an abundance of pro-inflammatory bacteria (e.g., Enterococcus faecium and Romboutsia timonensis) and a depletion of short-chain fatty acid (SCFA)-producing species (Ruminococcus bromii and Faecalibacterium duncaniae), potentially contributing to heightened neuroinflammation and disease progression. Relapsing MS exhibited microbial shifts indicative of immune dysregulation, including increased Clostridium saudiense and decreased levels of the gut-protective Faecalibacterium butyricigenerans. Functional analysis linked these microbial alterations to oxidative stress, neurotransmitter imbalance, and suppressed lipid and carbohydrate metabolism. These findings underscore the role of gut microbiota dysbiosis in MS pathogenesis and, by focusing on an underexplored Egyptian cohort, highlight region-specific microbial shifts that may inform targeted therapeutic strategies for both Progressive and Relapsing forms of MS.
多发性硬化症(MS)是一种中枢神经系统(CNS)的慢性自身免疫性疾病,其特征为神经炎症和神经退行性变。新出现的证据将肠道微生物群失调与免疫失调及MS进展联系起来。虽然在西方人群中已经进行了广泛研究,但仍需要进行区域特异性研究,以评估当地遗传和环境因素的影响。本研究使用牛津纳米孔测序技术调查埃及MS患者的肠道微生物群变化,以识别与疾病进展相关的微生物特征。使用全长16S rRNA基因的长读长牛津纳米孔测序技术,分析了33例新诊断的MS患者(20例复发缓解型MS [RRM]和13例进展型MS [PMS])以及10名健康对照者的粪便样本。MS患者的微生物丰富度增加但均匀度降低,具有独特的肠道微生物组特征。进展型MS的特征是促炎细菌(如粪肠球菌和蒂氏罗姆布茨菌)丰富,而产生短链脂肪酸(SCFA)的物种(布氏瘤胃球菌和邓肯粪杆菌)减少,这可能导致神经炎症加剧和疾病进展。复发型MS表现出指示免疫失调的微生物变化,包括沙特梭菌增加和具有肠道保护作用的丁酸粪杆菌水平降低。功能分析将这些微生物变化与氧化应激、神经递质失衡以及脂质和碳水化合物代谢受抑制联系起来。这些发现强调了肠道微生物群失调在MS发病机制中的作用,并且通过关注一个未被充分研究的埃及队列,突出了区域特异性的微生物变化,这可能为进展型和复发型MS的靶向治疗策略提供依据。